Stock Movers Lululemon Lower, Trade Desk Inches Higher, Eli Lilly Tumbles
5 snips
Mar 17, 2026 Lululemon’s sales outlook and board shakeup spark discussion about product quality and rising rivals. Eli Lilly faces a downgrade amid worries that obesity drug expectations and pricing are getting overheated. The Trade Desk weathers reports that major agencies are steering clients away, raising questions about competitive pressures.
AI Snips
Chapters
Transcript
Episode notes
Lululemon Outlook Highlights Execution And Competition
- Lululemon faces ongoing execution and competitive challenges after giving a weak outlook and projecting fiscal sales of $11.35–$11.5 billion with EPS below expectations.
- Net revenue in the Americas fell 4% in Q4 and founder Chip Wilson is pushing strategic changes while the board added former Levi CEO Chip Berg.
Rivals' Early Data Fuels Debate Over Lilly's Future
- Market debate is split on whether competitive drug updates materially threaten Lilly's long-term position, with some data seen as early-stage but rivals' progress flagged as highly competitive.
- BMO described Structure Therapeutics' early data as a highly competitive update for rival medicines, fueling the debate.
HSBC Downgrade Signals Pricing Risk For Lilly
- Eli Lilly plunged about 6% after HSBC downgraded the stock, arguing expectations for weight-loss drug pricing are overinflated amid competitive price cuts.
- HSBC cut the rating to sell and set a $850 target, saying Wall Street is too optimistic as rivals like Novo Nordisk compete on price.